Edward Nash
Stock Analyst at Canaccord Genuity
(4.91)
# 259
Out of 5,126 analysts
408
Total ratings
49.3%
Success rate
24.1%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterated: Buy | $111 → $107 | $20.95 | +410.74% | 5 | Nov 10, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $60 → $68 | $30.15 | +125.54% | 15 | Nov 9, 2026 | |
| KLRA Kailera Therapeutics | Initiated Coverage: Buy | $44 | $14.38 | +205.98% | 1 | Nov 9, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterated: Buy | $5 | $0.568 | +780.28% | 21 | Nov 9, 2026 | |
| ACRS Aclaris Therapeutics | Reiterated: Buy | $13 | $4.34 | +199.54% | 3 | Nov 6, 2026 | |
| CORT Corcept Therapeutics | Reiterated: Buy | $161 | $74.53 | +116.02% | 59 | Nov 5, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $60 → $57 | $50.53 | +12.80% | 4 | Nov 5, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $612 → $633 | $433.03 | +46.18% | 44 | Nov 4, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | $70 → $72 | $52.04 | +38.36% | 43 | Nov 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $129 | $134.84 | -4.33% | 7 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $106 → $118 | $28.44 | +314.91% | 14 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 | $95.76 | +2.34% | 7 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14.02 | $1.46 | +860.45% | 29 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.6889 | +770.95% | 6 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $11.41 | +390.80% | 13 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $21 | $4.01 | +423.69% | 15 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $153 | $38.44 | +298.02% | 4 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $0.7776 | +285.80% | 16 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $2.14 | +1,068.22% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $4.07 | n/a | 8 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $4.13 | n/a | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $1 | $0.0001 | n/a | 2 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $5.04 | n/a | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 | $1.18 | n/a | 1 | Jun 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 → $39 | $3.42 | n/a | 9 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $176 | $16.68 | n/a | 15 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $64 | $24.59 | n/a | 2 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $126 → $117 | $58.33 | n/a | 14 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $71 | $16.70 | n/a | 11 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $156 | $48.77 | n/a | 1 | Sep 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $132 | $977.58 | n/a | 1 | Sep 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $4 | $16.64 | n/a | 3 | Jun 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $13.01 | n/a | 1 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $23 | $2.30 | n/a | 2 | May 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $0.0001 | n/a | 1 | Sep 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $2 | $0.0001 | n/a | 2 | May 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $6 | $2.73 | n/a | 8 | May 5, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $8.12 | n/a | 3 | Mar 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $11 | $4.87 | n/a | 3 | Sep 4, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.106 | n/a | 1 | Jun 17, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $21.77 | n/a | 2 | May 3, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $18.37 | n/a | 1 | Jan 28, 2013 |
Structure Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $111 → $107
Current: $20.95
Upside: +410.74%
Celldex Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $60 → $68
Current: $30.15
Upside: +125.54%
Kailera Therapeutics
Nov 9, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $14.38
Upside: +205.98%
Rani Therapeutics Holdings
Nov 9, 2026
Reiterated: Buy
Price Target: $5
Current: $0.568
Upside: +780.28%
Aclaris Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $13
Current: $4.34
Upside: +199.54%
Corcept Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $161
Current: $74.53
Upside: +116.02%
First Tracks Biotherapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $60 → $57
Current: $50.53
Upside: +12.80%
Madrigal Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $612 → $633
Current: $433.03
Upside: +46.18%
Travere Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $70 → $72
Current: $52.04
Upside: +38.36%
Kymera Therapeutics
Nov 3, 2026
Reiterated: Buy
Price Target: $129
Current: $134.84
Upside: -4.33%
Oct 30, 2026
Reiterated: Buy
Price Target: $106 → $118
Current: $28.44
Upside: +314.91%
Oct 28, 2026
Reiterated: Buy
Price Target: $98
Current: $95.76
Upside: +2.34%
Oct 28, 2026
Reiterated: Buy
Price Target: $14.02
Current: $1.46
Upside: +860.45%
Oct 1, 2026
Reiterated: Buy
Price Target: $6
Current: $0.6889
Upside: +770.95%
Oct 1, 2026
Reiterated: Buy
Price Target: $56
Current: $11.41
Upside: +390.80%
Sep 29, 2026
Reiterated: Buy
Price Target: $20 → $21
Current: $4.01
Upside: +423.69%
Sep 28, 2026
Reiterated: Buy
Price Target: $153
Current: $38.44
Upside: +298.02%
Aug 13, 2026
Reiterated: Hold
Price Target: $3
Current: $0.7776
Upside: +285.80%
May 14, 2026
Rated: Buy
Price Target: $25
Current: $2.14
Upside: +1,068.22%
Oct 2, 2024
Reiterated: Buy
Price Target: $9
Current: $4.07
Upside: n/a
May 17, 2023
Reiterated: Hold
Price Target: $2
Current: $4.13
Upside: n/a
Jul 29, 2022
Downgraded: Hold
Price Target: $12 → $1
Current: $0.0001
Upside: n/a
May 18, 2021
Reiterated: Buy
Price Target: $25
Current: $5.04
Upside: n/a
Jun 5, 2019
Downgraded: Hold
Price Target: $5
Current: $1.18
Upside: n/a
May 20, 2019
Reiterated: Buy
Price Target: $60 → $39
Current: $3.42
Upside: n/a
Feb 27, 2019
Reiterated: Buy
Price Target: $176
Current: $16.68
Upside: n/a
Feb 26, 2019
Reiterated: Buy
Price Target: $48 → $64
Current: $24.59
Upside: n/a
Feb 25, 2019
Reiterated: Buy
Price Target: $126 → $117
Current: $58.33
Upside: n/a
Jan 23, 2019
Reiterated: Buy
Price Target: $54 → $71
Current: $16.70
Upside: n/a
Sep 24, 2018
Reiterated: Buy
Price Target: $156
Current: $48.77
Upside: n/a
Sep 17, 2018
Reiterated: Buy
Price Target: $132
Current: $977.58
Upside: n/a
Jun 27, 2018
Downgraded: Hold
Price Target: $22 → $4
Current: $16.64
Upside: n/a
Jun 25, 2018
Initiated Coverage: Buy
Price Target: $26
Current: $13.01
Upside: n/a
May 16, 2018
Reiterated: Buy
Price Target: $26 → $23
Current: $2.30
Upside: n/a
Sep 18, 2017
Reiterated: Buy
Price Target: $24
Current: $0.0001
Upside: n/a
May 16, 2017
Reiterated: Hold
Price Target: $1 → $2
Current: $0.0001
Upside: n/a
May 5, 2017
Reiterated: Hold
Price Target: $3 → $6
Current: $2.73
Upside: n/a
Mar 7, 2017
Reiterated: Hold
Price Target: $9
Current: $8.12
Upside: n/a
Sep 4, 2014
Downgraded: Hold
Price Target: $14 → $11
Current: $4.87
Upside: n/a
Jun 17, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $0.106
Upside: n/a
May 3, 2013
Downgraded: Sell
Price Target: n/a
Current: $21.77
Upside: n/a
Jan 28, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $18.37
Upside: n/a